## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## **Single Technology Appraisal**

# Darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer ID1443

## Final stakeholder list of consultees and commentators

Consultees	Commentators (no right to submit or
	appeal)
Company	General
Bayer (darolutamide)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	Allied Health Professionals Federation
Black Health Agency	<ul> <li>Board of Community Health Councils</li> </ul>
Bob Champion Cancer Trust	in Wales
Cancer Black Care	<ul> <li>British National Formulary</li> </ul>
Cancer Equality	<ul> <li>Care Quality Commission</li> </ul>
HAWC – Help Adolescents with	<ul> <li>Department of Health, Social Services</li> </ul>
Cancer	and Public Safety for Northern Ireland
Helen Rollason Cancer Charity	Healthcare Improvement Scotland
Independent Cancer Patients Voice	Medicines and Healthcare products
Macmillan Cancer Support	Regulatory Agency
Maggie's Centres	National Association of Primary Care
Marie Curie	National Pharmacy Association
Muslim Council of Britain	NHS Alliance
Orchid	NHS Confederation
Pelican Cancer Foundation	Scottish Medicines Consortium
PCaSO - Prostate Cancer Support	Welsh Health Specialised Services     ""
Organisation	Committee
Prostate Cancer UK     Prostate Usin Association	Possible comparator companies
<ul><li>Prostate Help Association</li><li>South Asian Health Foundation</li></ul>	Accord (bicalutamide)
	<ul> <li>Accord (bleafdtarride)</li> <li>AstraZeneca UK (bicalutamide,</li> </ul>
<ul><li>Specialised Healthcare Alliance</li><li>Tackle Prostate Cancer</li></ul>	goserelin)
_	Bayer (cyproterone acetate)
Tenovus Cancer Care	Concordia International (leuprorelin)
Professional groups	Ferring Pharmaceuticals (degarelix,
Association of Anaesthetists	triptorelin)
Association of Cancer Physicians	Generics UK T/A Mylan (flutamide)
Association of Surgeons of Great	Ipsen (triptorelin)
Britain and Ireland	Orion Pharma UK (histrelin)
British Association of Urological	Sanofi (buserelin)

Final stakeholder list for the technology appraisal of darolutamide with androgen deprivation therapy for treating non-metastatic hormone-relapsed prostate cancer ID1443 Issue date: January 2020

#### Consultees Commentators (no right to submit or appeal) Nurses Sunpharma (bicalutamide) British Association of Urological Takeda UK (leuprorelin) Surgeons Wockhardt UK (cyproterone acetate) **British Geriatrics Society** Zentiva (bicalutamide) British Institute of Radiology British Prostate Group Relevant research groups British Psychosocial Oncology Cochrane Urology Society Everyman Genomics England British Uro-Oncology Group • Cancer Research UK Institute of Cancer Research Prostate Cancer Advisory group MRC Clinical Trials Unit Royal College of Anaesthetists National Cancer Research Institute Royal College of General National Cancer Research Network **Practitioners** National Institute for Health Research Royal College of Nursing Ovarian & Prostate Cancer Research Royal College of Pathologists Trust Royal College of Physicians Pro Cancer Research Fund Royal College of Radiologists **Prostate Cancer Research Centre** Royal College of Surgeons Royal Pharmaceutical Society Associated Public Health groups • Public Health England Royal Society of Medicine • Public Health Wales Society and College of Radiographers **UK Clinical Pharmacy Association** UK Health Forum **UK Oncology Nursing Society** Urology Foundation

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Others

CareNHS England

Department of Health and Social

NHS South Reading CCG

NHS Swindon CCG
Welsh Government



#### Definitions:

### Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Document (FAD).

All non-company consultees are invited to submit a statement<sup>1</sup>, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Document (FAD).

## Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland;; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary.

All non-company commentators are invited to nominate clinical or patient experts.

<sup>&</sup>lt;sup>1</sup> Non company consultees are invited to submit statements relevant to the group they are representing.